- Medicine Name: Arexvy
- API: Respiratory Syncytial Virus Vaccine, Adjuvanted
- Dosage Form & Strength: Suspension for intramuscular injection
- Manufactured By: GlaxoSmithKline Biologicals
Arexvy (respiratory syncytial virus vaccine, adjuvanted) is a vaccine used for active immunization for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus in individuals aged 60 years and older.
Recommended Dosage: The recommended dose of Arexvy is 0.5 mL administered by intramuscular (IM) injection only, preferably in the upper arm or deltoid muscle. The requirement for revaccination with a subsequent dose of Arexvy (IM) intramuscular injection has not been developed. Do not administer it to anyone with a known history of a severe allergic reaction (e.g., anaphylaxis) to any component of Arexvy.
All Trademarks and Brands that appear on the website belong to their respective owners and indianpharmanetwork does not lay any claim on them we only provide Information.